Metalloprotein inhibitors for the treatment of human diseases

Current Topics in Medicinal Chemistry

Volumn 16, Issue 4, 2016, Pages 384-396

  Yang, Yang ^a   Hu, Xue Qin ^a   Li, Qing Shan ^a   Zhang, Xing Xing ^a   Ruan, Ban Feng ^a   Xu, Jun ^a,b   Liao, Chenzhong ^a  

^a HEFEI UNIVERSITY OF TECHNOLOGY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chelating; Drug design; Drug development; Magnesium; Metalloprotein; Zinc

Indexed keywords

ACETAZOLAMIDE; BENDROFLUMETHIAZIDE; BENZTHIAZIDE; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CHLOROTHIAZIDE; CYCLOTHIAZIDE; DICLOFENAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DORZOLAMIDE; ENZYME INHIBITOR; FUROSEMIDE; HISTONE DEACETYLASE; HYDROCHLOROTHIAZIDE; HYDROFLUMETHIAZIDE; INTEGRASE; LIPOXYGENASE; MATRIX METALLOPROTEINASE; METALLOPROTEIN INHIBITOR; METHAZOLAMIDE; METHYCLOTHIAZIDE; QUINETHAZONE; ROMIDEPSIN; STEROL 14ALPHA DEMETHYLASE; TOPIRAMATE; TRICHLORMETHIAZIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZINC ION; ZONISAMIDE; METALLOPROTEIN; PROTEINASE INHIBITOR;

ANTIMICROBIAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOSYNTHESIS; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DRUG BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; HYPERTENSION; METABOLISM; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HIV INFECTIONS; NEOPLASMS; STRUCTURE ACTIVITY RELATION;

HIV INFECTIONS; HUMANS; HYPERTENSION; METALLOPROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84979097462     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150813145218     Document Type: Article

References (63)

1. Waldron, K.J.; Robinson, N.J. How do bacterial cells ensure that metalloproteins get the correct metal? Nat. Rev. Microbiol., 2009, 7 (2), 25-35.
2. Shi, W.; Chance, M.R. Metallomics and metalloproteomics. Cell Mol. Life Sci., 2008, 65 (19), 3040-3048.
3. Martin, D.P.; Hann, Z.S.; Cohen, S.M. Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site. Inorg. Chem., 2013, 52 (21), 12207-12215.
4. Supuran, C.T.; Winum, J.-Y. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. John Wiley & Sons, Inc., 2009.
5. Anzellotti, A.I.; Farrell, N.P. Zinc metalloproteins as medicinal targets. Chem. Soc. Rev., 2008, 37 (8), 1629-1651.
6. Coleman, J.E., Zinc enzymes. Curr. Opin. Chem. Biol., 1998, 2 (2), 222-234.
7. Irwin, J.J.; Raushel, F.M.; Shoichet, B.K. Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry, 2005, 44 (37), 12316-12328.
8. Supuran, C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov., 2008, 7 (2), 168-181.
9. Supuran, C.T. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med. Chem., 2011, 3 (9), 1165-1180.
10. Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov., 2011, 10 (10), 767-777.
11. Parks, S.K.; Chiche, J.; Pouyssegur, J. pH control mechanisms of tumor survival and growth. J. Cell Physiol., 2011, 226 (2), 299-308.
12. Ward, C.; Langdon, S.P.; Mullen, P.; Harris, A.L.; Harrison, D.J.; Supuran, C.T.; Kunkler, I.H. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat. Rev., 2013, 39 (2), 171-179.
13. Jacobsen, J.A.; Fullagar, J.L.; Miller, M.T.; Cohen, S.M. Identifying chelators for metalloprotein inhibitors using a fragment-based approach. J. Med. Chem., 2011, 54 (2), 591-602.
14. Fisher, S.Z.; Aggarwal, M.; Kovalevsky, A.Y.; Silverman, D.N.; McKenna, R. Neutron diffraction of acetazolamide-bound human carbonic anhydrase II reveals atomic details of drug binding. J. Am. Chem. Soc., 2012, 134 (36), 14726-14729.
15. Scolnick, L.R.; Clements, A.M.; Liao, J.; Crenshaw, L.; Hellberg, M.; May, J.; Dean, T.R.; Christianson, D.W. Novel Binding Mode of Hydroxamate Inhibitors to Human Carbonic Anhydrase II. J. Am. Chem. Soc., 1997, 119 (4), 850-851.
16. Giannini, G.; Cabri, W.; Fattorusso, C.; Rodriquez, M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med. Chem., 2012, 4 (11), 1439-1460.
17. Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med. Chem., 2012, 4 (4), 505-524.
18. Thaler, F. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. Pharm. Pat. Anal., 2012, 1 (1), 75-90.
19. de Ruijter, A.J.; van Gennip, A.H.; Caron, H.N.; Kemp, S.; van Kuilenburg, A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 2003, 370 (Pt 3), 737-749.
20. Weichert, W.; Roske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Fritzsche, F.R.; Niesporek, S.; Denkert, C.; Dietel, M.; Kristiansen, G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer, 2008, 98 (3), 604-610.
21. Minucci, S.; Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 2006, 6 (1), 38-51.
22. Lauffer, B.E.; Mintzer, R.; Fong, R.; Mukund, S.; Tam, C.; Zilberleyb, I.; Flicke, B.; Ritscher, A.; Fedorowicz, G.; Vallero, R.; Ortwine, D.F.; Gunzner, J.; Modrusan, Z.; Neumann, L.; Koth, C.M.; Lupardus, P.J.; Kaminker, J.S.; Heise, C.E.; Steiner, P. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J. Biol. Chem., 2013, 288 (37), 26926-26943.
23. Cole, K.E.; Dowling, D.P.; Boone, M.A.; Phillips, A.J.; Christianson, D.W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc., 2011, 133, (32), 12474-12477.
24. Bressi, J.C.; Jennings, A.J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C.E.; Navre, M.; Gangloff, A.R. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg. Med. Chem. Lett., 2010, 20 (10), 3142-3145.
25. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N.P.; Lewis, T.A.; Maglathin, R.L.; McLean, T.H.; Bochkarev, A.; Plotnikov, A.N.; Vedadi, M.; Arrowsmith, C.H., Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem., 2008, 283 (17), 11355-11363.
26. Yao, Y.W.; Liao, C.H.; Li, Z.; Wang, Z.; Sun, Q.; Liu, C.P.; Yang, Y.; Tu, Z.C.; Jiang, S. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. Eur. J. Med. Chem., 2014, 86, 639-652.
27. Akif, M.; Georgiadis, D.; Mahajan, A.; Dive, V.; Sturrock, E.D.; Isaac, R.E.; Acharya, K.R. High-resolution crystal structures of Drosophila melanogaster angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive drugs. J. Mol. Biol., 2010, 400 (3), 502-517.
28. Duchackova, L.; Roithova, J. The interaction of zinc(II) and hydroxamic acids and a metal-triggered Lossen rearrangement. Chemistry, 2009, 15 (48), 13399-13405.
29. Natesh, R.; Schwager, S.L.; Evans, H.R.; Sturrock, E.D.; Acharya, K.R. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin Iconverting enzyme. Biochemistry, 2004, 43 (27), 8718-8724.
30. Marchand, C.; Maddali, K.; Metifiot, M.; Pommier, Y. HIV-1 IN inhibitors: 2010 update and perspectives. Curr. Top. Med. Chem., 2009, 9 (11), 1016-1037.
31. Liao, C.; Nicklaus, M.C. Tautomerism and magnesium chelation of HIV-1 integrase inhibitors: a theoretical study. ChemMedChem, 2010, 5 (7), 1053-1066.
32. Liao, C.; Marchand, C.; Burke, T.R., Jr.; Pommier, Y.; Nicklaus, M.C. Authentic HIV-1 integrase inhibitors. Future Med. Chem., 2010, 2 (7), 1107-1122.
33. Krishnan, L.; Li, X.; Naraharisetty, H.L.; Hare, S.; Cherepanov, P.; Engelman, A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci. USA, 2010, 107 (36), 15910-15915.
34. Hare, S.; Vos, A.M.; Clayton, R.F.; Thuring, J.W.; Cummings, M.D.; Cherepanov, P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. USA, 2010, 107 (46), 20057-20062.
35. Hare, S.; Smith, S.J.; Metifiot, M.; Jaxa-Chamiec, A.; Pommier, Y.; Hughes, S.H.; Cherepanov, P. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol., 2011, 80 (4), 565-572.
36. Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature, 2010, 464 (7286), 232-236.
37. Metifiot, M.; Marchand, C.; Maddali, K.; Pommier, Y. Resistance to integrase inhibitors. Viruses, 2010, 2 (7), 1347-1366.
38. Liao, C.; Nicklaus, M.C. Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med. Chem., 2010, 2 (7), 1123-1140.
39. Cirilli, M.; Gallina, C.; Gavuzzo, E.; Giordano, C.; Gomis-Ruth, F.X.; Gorini, B.; Kress, L.F.; Mazza, F.; Paradisi, M.P.; Pochetti, G.; Politi, V. 2 angstrom X-ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retrobinding mode. FEBS Lett., 1997, 418 (3), 319-322.
40. Gomis-Ruth, F.X.; Meyer, E.F.; Kress, L.F.; Politi, V. Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor alpha convertase inhibitors. Protein Sci., 1998, 7 (2), 283-292.
41. Thompson, A.A.; Jiao, G.S.; Kim, S.; Thai, A.; Cregar-Hernandez, L.; Margosiak, S.A.; Johnson, A.T.; Han, G.W.; O'Malley, S.; Stevens, R.C. Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. Biochemistry, 2011, 50 (19), 4019-4028.
42. Wlodarczyk, N.; Le Broc-Ryckewaert, D.; Gilleron, P.; Lemoine, A.; Farce, A.; Chavatte, P.; Dubois, J.; Pommery, N.; Henichart, J.P.; Furman, C.; Millet, R. Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer. J. Med. Chem., 2011, 54 (5), 1178-1190.
43. Reid, T.S.; Beese, L.S. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry, 2004, 43 (22), 6877-6884.
44. Fisher, J.F.; Mobashery, S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev., 2006, 25 (1), 115-136.
45. Nara, H.; Sato, K.; Naito, T.; Mototani, H.; Oki, H.; Yamamoto, Y.; Kuno, H.; Santou, T.; Kanzaki, N.; Terauchi, J.; Uchikawa, O.; Kori, M. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. J. Med. Chem., 2014, 57 (21), 8886-8902.
46. Dragoni, E.; Calderone, V.; Fragai, M.; Jaiswal, R.; Luchinat, C.; Nativi, C. Biotin-tagged probes for MMP expression and activation: design, synthesis, and binding properties. Bioconjug Chem., 2009, 20 (4), 719-727.
47. Aleksandrov, A.; Proft, J.; Hinrichs, W.; Simonson, T. Protonation patterns in tetracycline:tet repressor recognition: simulations and experiments. Chembiochem, 2007, 8 (6), 675-685.
48. Hiraiwa, Y.; Saito, J.; Watanabe, T.; Yamada, M.; Morinaka, A.; Fukushima, T.; Kudo, T. X-ray crystallographic analysis of IMP-1 metallo-beta-lactamase complexed with a 3-aminophthalic acid derivative, structure-based drug design, and synthesis of 3,6-disubstituted phthalic acid derivative inhibitors. Bioorg. Med. Chem. Lett., 2014, 24 (20), 4891-4894.
49. McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.R. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 2014, 371 (11), 993-1004.
50. Kario, K.; Sun, N.; Chiang, F.T.; Supasyndh, O.; Baek, S.H.; Inubushi-Molessa, A.; Zhang, Y.; Gotou, H.; Lefkowitz, M.; Zhang, J. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension, 2014, 63 (4), 698-705.
51. Oefner, C.; Roques, B.P.; Fournie-Zaluski, M.C.; Dale, G.E. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr D., 2004, 60, 392-396.
52. Mochizuki, S.; Okada, Y. ADAMs in cancer cell proliferation and progression. Cancer Sci., 2007, 98 (5), 621-628.
53. Kenny, P.A. TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation, 2007, 75 (9), 800-808.
54. Niu, X.; Umland, S.; Ingram, R.; Beyer, B.M.; Liu, Y.H.; Sun, J.; Lundell, D.; Orth, P. IK682, a tight binding inhibitor of TACE. Arch. Biochem. Biophys., 2006, 451 (1), 43-50.
55. Luci, D.K.; Jameson, J.B.; Yasgar, A.; Diaz, G.; Joshi, N.; Kantz, A.; Markham, K.; Perry, S.; Kuhn, N.; Yeung, J.; Kerns, E.H.; Schultz, L.; Holinstat, M.; Nadler, J.L.; Taylor-Fishwick, D.A.; Jadhav, A.; Simeonov, A.; Holman, T.R.; Maloney, D.J. Synthesis and Structure-Activity Relationship Studies of 4-((2-Hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase. J. Med. Chem., 2014, 57 (2), 495-506.
56. Neau, D.B.; Bender, G.; Boeglin, W.E.; Bartlett, S.G.; Brash, A.R.; Newcomer, M.E. Crystal structure of a lipoxygenase in complex with substrate: the arachidonic acid-binding site of 8Rlipoxygenase. J. Biol. Chem., 2014, 289, (46), 31905-31913.
57. Cao, L.L.; Song, W.G.; De Clercq, E.; Zhan, P.; Liu, X.Y. Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors. Curr. Med. Chem., 2014, 21 (17), 1956-1967.
58. Vernekar, S.K.; Liu, Z.; Nagy, E.; Miller, L.; Kirby, K.A.; Wilson, D.J.; Kankanala, J.; Sarafianos, S.G.; Parniak, M.A.; Wang, Z. Design, Synthesis, Biochemical, and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxylisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities. J. Med. Chem., 2015, 58(2):651-64.
59. Kirschberg, T.A.; Balakrishnan, M.; Squires, N.H.; Barnes, T.; Brendza, K.M.; Chen, X.; Eisenberg, E.J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu, X.; Mak, J.; Perry, J.K.; Wang, M.; Watkins, W.J.; Lansdon, E.B. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J. Med. Chem., 2009, 52 (19), 5781-5784.
60. Chen, C.K.; Leung, S.S.F.; Guilbert, C.; Jacobson, M.P.; McKerrow, J.H.; Podust, L.M. Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole. Plos Negl. Trop. D., 2010, 4 (4), e651.
61. Sandanayaka, V.; Mamat, B.; Mishra, R.K.; Winger, J.; Krohn, M.; Zhou, L.M.; Keyvan, M.; Enache, L.; Sullins, D.; Onua, E.; Zhang, J.; Halldorsdottir, G.; Sigthorsdottir, H.; Thorlaksdottir, A.; Sigthorsson, G.; Thorsteinnsdottir, M.; Davies, D.R.; Stewart, L.J.; Zembower, D.E.; Andresson, T.; Kiselyov, A.S.; Singh, J.; Gurney, M.E. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy] methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J. Med. Chem., 2010, 53 (2), 573-585.
62. Choi, H.; Kang, H.; Park, H. MetLigDB: a web-based database for the identification of chemical groups to design metalloprotein inhibitors. J. Appl. Crystallogr., 2011, 44, 878-881.
63. Liao, C.Z.; Yao, R.S. Diversity evolution and jump of Polo-like kinase 1 inhibitors. Sci. China Chem., 2013, 56 (10), 1392-1401.